Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368918 | 1.00 | CA2 (0.49) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL2159214 | 1.00 | CA2 (0.49) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL754742 | 0.88 | CA2 (0.46) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7154999 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL18817541 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL949218 | 0.82 | — | — | |
| SCHEMBL479143 | 0.82 | — | — | |
| SCHEMBL3862320 | 0.82 | — | — | |
| SCHEMBL13130046 | 0.82 | CA2 (0.47) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL4475938 | 0.80 | CA2 (0.46) | CA2ALDH1A1NPSR1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536576-A | Sulfonylbenzamide derivatives, conjugates thereof, preparation methods and applications of derivatives and conjugates | 江苏恒瑞医药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115260152-A | Sulfonylbenzamide derivatives, conjugates thereof, preparation methods and applications of derivatives and conjugates | 江苏恒瑞医药股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8618290-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2536731-A1 | SUBSTITUTED SPIROINDOLINONES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-5531978-A | CHELATE COMPOUNDS, IMAGING | NYCOMED IMAGING AS (NO) | 1996-07-02 | — | — | US | disclosed |
| US-5419893-A | Aminopolycarboxylic acids and derivatives thereof for magnetic resonance imaging | NYCOMED IMAGING AS (NO) | 1995-05-30 | — | — | US | disclosed |
| US-5198208-A | Chelate compounds for diagnosis by magnetic resonance imaging, ultrasound or radiation therapy | NYCOMED IMAGING AS (NO) | 1993-03-30 | — | — | US | disclosed |
| EP-0299795-B1 | AMINOPOLYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | NYCOMED AS (NO) | 1992-03-18 | — | — | EP | disclosed |
| EP-0466200-A1 | Aminocarboxylic acids and derivatives thereof | NYCOMED IMAGING AS (NO) | 1992-01-15 | — | — | EP | disclosed |
| EP-0453507-A1 | CHELATING AGENT DERIVATIVES | NYCOMED IMAGING AS (NO) | 1991-10-30 | — | — | EP | disclosed |
| WO-1990008134-A1 | CHELATING AGENT DERIVATIVES | NYCOMED AS (NO) | 1990-07-26 | — | — | WO | disclosed |
| WO-1989000557-A1 | AMINOPOLYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | COCKBAIN, JULIAN, RODERICK, MICHAELSON (GB) | 1989-01-26 | — | — | WO | disclosed |
| US-4001323-A | RADIOPAQUE MATERIALS | SAVAC AG (CH) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | CA2 4306/4885ALDH1A1 3718/4885NPSR1 4438/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.